Confronting the barriers to develop novel vaccines against brucellosis

Autores
Oliveira, Sérgio Costa; Giambartolomei, Guillermo Hernan; Cassataro, Juliana
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Brucellosis is an important zoonotic disease of nearly worldwide distribution. This pathogen causes abortion in domestic animals and undulant fever, arthritis, endocarditis and meningitis in humans. Currently, there is no vaccine licensed for brucellosis in humans. Furthermore, control of brucellosis in the human population relies on the control of animal disease. Available animal vaccines may cause disease and in some cases have limited efficacy. This article discusses recent studies in the development of recombinant protein, DNA and live-attenuated vaccines against brucellosis. Furthermore, we call the attention of the scientific community, government and industry professionals to the fact that for these novel vaccine initiatives to become licensed products they need to be effective in natural hosts and bypass the regulatory barriers present in several countries. © 2011 Expert Reviews Ltd.
Fil: Oliveira, Sérgio Costa. Universidade Federal de Minas Gerais; Brasil
Fil: Giambartolomei, Guillermo Hernan. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Cassataro, Juliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Materia
Brucella Abortus
Brucellosis
Dna Vaccine
Live-Attenuated Vaccine
Recombinant Protein Vaccine
Vaccine
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/67556
Acceder
id CONICETDig_4922204a90bc722d67a587847129536e
oai_identifier_str oai:ri.conicet.gov.ar:11336/67556
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Confronting the barriers to develop novel vaccines against brucellosisOliveira, Sérgio CostaGiambartolomei, Guillermo HernanCassataro, JulianaBrucella AbortusBrucellosisDna VaccineLive-Attenuated VaccineRecombinant Protein VaccineVaccinehttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Brucellosis is an important zoonotic disease of nearly worldwide distribution. This pathogen causes abortion in domestic animals and undulant fever, arthritis, endocarditis and meningitis in humans. Currently, there is no vaccine licensed for brucellosis in humans. Furthermore, control of brucellosis in the human population relies on the control of animal disease. Available animal vaccines may cause disease and in some cases have limited efficacy. This article discusses recent studies in the development of recombinant protein, DNA and live-attenuated vaccines against brucellosis. Furthermore, we call the attention of the scientific community, government and industry professionals to the fact that for these novel vaccine initiatives to become licensed products they need to be effective in natural hosts and bypass the regulatory barriers present in several countries. © 2011 Expert Reviews Ltd.Fil: Oliveira, Sérgio Costa. Universidade Federal de Minas Gerais; BrasilFil: Giambartolomei, Guillermo Hernan. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Cassataro, Juliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaExpert Reviews2011-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/67556Oliveira, Sérgio Costa; Giambartolomei, Guillermo Hernan; Cassataro, Juliana; Confronting the barriers to develop novel vaccines against brucellosis; Expert Reviews; Expert Review Of Vaccines; 10; 9; 9-2011; 1291-13051476-0584CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1586/erv.11.110info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1586/erv.11.110?journalCode=ierv20info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:04:50Zoai:ri.conicet.gov.ar:11336/67556instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:04:50.696CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Confronting the barriers to develop novel vaccines against brucellosis
title Confronting the barriers to develop novel vaccines against brucellosis
spellingShingle Confronting the barriers to develop novel vaccines against brucellosis
Oliveira, Sérgio Costa
Brucella Abortus
Brucellosis
Dna Vaccine
Live-Attenuated Vaccine
Recombinant Protein Vaccine
Vaccine
title_short Confronting the barriers to develop novel vaccines against brucellosis
title_full Confronting the barriers to develop novel vaccines against brucellosis
title_fullStr Confronting the barriers to develop novel vaccines against brucellosis
title_full_unstemmed Confronting the barriers to develop novel vaccines against brucellosis
title_sort Confronting the barriers to develop novel vaccines against brucellosis
dc.creator.none.fl_str_mv Oliveira, Sérgio Costa
Giambartolomei, Guillermo Hernan
Cassataro, Juliana
author Oliveira, Sérgio Costa
author_facet Oliveira, Sérgio Costa
Giambartolomei, Guillermo Hernan
Cassataro, Juliana
author_role author
author2 Giambartolomei, Guillermo Hernan
Cassataro, Juliana
author2_role author
author
dc.subject.none.fl_str_mv Brucella Abortus
Brucellosis
Dna Vaccine
Live-Attenuated Vaccine
Recombinant Protein Vaccine
Vaccine
topic Brucella Abortus
Brucellosis
Dna Vaccine
Live-Attenuated Vaccine
Recombinant Protein Vaccine
Vaccine
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Brucellosis is an important zoonotic disease of nearly worldwide distribution. This pathogen causes abortion in domestic animals and undulant fever, arthritis, endocarditis and meningitis in humans. Currently, there is no vaccine licensed for brucellosis in humans. Furthermore, control of brucellosis in the human population relies on the control of animal disease. Available animal vaccines may cause disease and in some cases have limited efficacy. This article discusses recent studies in the development of recombinant protein, DNA and live-attenuated vaccines against brucellosis. Furthermore, we call the attention of the scientific community, government and industry professionals to the fact that for these novel vaccine initiatives to become licensed products they need to be effective in natural hosts and bypass the regulatory barriers present in several countries. © 2011 Expert Reviews Ltd.
Fil: Oliveira, Sérgio Costa. Universidade Federal de Minas Gerais; Brasil
Fil: Giambartolomei, Guillermo Hernan. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Cassataro, Juliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
description Brucellosis is an important zoonotic disease of nearly worldwide distribution. This pathogen causes abortion in domestic animals and undulant fever, arthritis, endocarditis and meningitis in humans. Currently, there is no vaccine licensed for brucellosis in humans. Furthermore, control of brucellosis in the human population relies on the control of animal disease. Available animal vaccines may cause disease and in some cases have limited efficacy. This article discusses recent studies in the development of recombinant protein, DNA and live-attenuated vaccines against brucellosis. Furthermore, we call the attention of the scientific community, government and industry professionals to the fact that for these novel vaccine initiatives to become licensed products they need to be effective in natural hosts and bypass the regulatory barriers present in several countries. © 2011 Expert Reviews Ltd.
publishDate 2011
dc.date.none.fl_str_mv 2011-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/67556
Oliveira, Sérgio Costa; Giambartolomei, Guillermo Hernan; Cassataro, Juliana; Confronting the barriers to develop novel vaccines against brucellosis; Expert Reviews; Expert Review Of Vaccines; 10; 9; 9-2011; 1291-1305
1476-0584
CONICET Digital
CONICET
url http://hdl.handle.net/11336/67556
identifier_str_mv Oliveira, Sérgio Costa; Giambartolomei, Guillermo Hernan; Cassataro, Juliana; Confronting the barriers to develop novel vaccines against brucellosis; Expert Reviews; Expert Review Of Vaccines; 10; 9; 9-2011; 1291-1305
1476-0584
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1586/erv.11.110
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1586/erv.11.110?journalCode=ierv20
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Expert Reviews
publisher.none.fl_str_mv Expert Reviews
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269878907568128
score 13.13397

Publicaciones similares